Welcome to our dedicated page for Blueprint Medicines SEC filings (Ticker: BPMC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing the science-heavy language in Blueprint Medicines’ SEC documents can feel like decoding a genomic sequence. Pipeline updates on selective kinase therapies, milestone payments from collaborations, and cash-runway disclosures are scattered across hundreds of pages. If finding that information in a 10-K or spotting insider buys before an FDA catalyst seems daunting, you’re not alone.
Stock Titan solves the problem. Our platform delivers AI-powered summaries that translate complex biotech terminology into plain English, then links you straight to the source form. Need the Blueprint Medicines quarterly earnings report 10-Q filing? One click. Curious about Blueprint Medicines insider trading Form 4 transactions or real-time alerts for Blueprint Medicines Form 4 insider transactions real-time? We surface them instantly. From a Blueprint Medicines annual report 10-K simplified to a Blueprint Medicines 8-K material events explained, our AI highlights what moves the stock.
Here’s what you can do on this page:
- Review every 10-K, 10-Q and 8-K with side-by-side Blueprint Medicines earnings report filing analysis
- Track Blueprint Medicines executive stock transactions Form 4 and monitor patterns before clinical readouts
- Dive into the Blueprint Medicines proxy statement executive compensation to see how management is rewarded for pipeline milestones
- Use our natural-language search—“understanding Blueprint Medicines SEC documents with AI” returns plain-spoken answers, not PDFs
Every filing posts within minutes of hitting EDGAR, and our expert layer explains valuation drivers like clinical trial spend, collaboration revenue and patent updates. Complex biotech filings, now clear and actionable.
Pentwater Capital Management LP and Matthew Halbower report beneficial ownership of 3,900,000 shares of Blueprint Medicines Corp common stock, representing 6.0% of the outstanding class based on 64,733,629 shares outstanding. The filing states the shares are directly held by the Pentwater Funds and that voting and dispositive power over these shares is shared (no sole voting or dispositive power reported). The Investment Manager is organized in Delaware and Mr. Halbower is a U.S. citizen; the business office for the reporting persons is 1001 10th Avenue South, Suite 216, Naples, FL. The statement certifies the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing control.
T. Rowe Price Associates, Inc. filed Amendment No. 9 to a Schedule 13G disclosing its holdings in Blueprint Medicines Corp common stock. The filing reports an aggregate beneficial ownership of 1,465,036 shares, representing 2.3% of the class, with sole voting power of 1,429,561 shares and sole dispositive power of 1,459,988 shares. The statement affirms the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The form is signed by Ellen York, Vice President, dated 08/14/2025.
Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 375,000 shares of Blueprint Medicines Corp common stock, equal to 0.6% of the class based on 64,733,629 shares outstanding as reported by the issuer. The filing shows both reporting persons have sole voting power and sole dispositive power for the reported shares. Avoro is identified as an investment adviser and Dr. Aghazadeh as the portfolio manager and controlling person; the shares are held for investment purposes on behalf of Avoro Life Sciences Fund LLC and are stated to be held in the ordinary course of business with no intent to change or influence control.
FAQ
What is the current stock price of Blueprint Medicines (BPMC)?
What is the market cap of Blueprint Medicines (BPMC)?
